基于国家中药复方专利探讨非酒精性脂肪性肝病的用药规律

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (996 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore medication rule of non-alcoholic fatty liver disease based on national patent of traditional Chinese medicine compound. Methods “Non-alcoholic fatty liver disease”, “traditional Chinese medicine” and “prescription” were the key words. The published patent compounds of traditional Chinese medicine in treating non-alcoholic fatty liver disease of patent database from database establishment to July 2021 were searched. Drug statistics, compatibility analysis, cluster analysis and complex network analysis were used to study patent compound based on ancient and modern medical records cloud platform. Results A total of 127 patents were included, involving 317 herbs. Salviae Miltiorrhizae Radix et Rhizoma was the most frequent herb. The medicine property was mostly warm. Herbal medicine mainly tasted bitter, sweet and pungent, which mostly belonged to liver and spleen meridians. Most of drug effects were clearing away heat and toxin, removing turbidity and reducing lipid, and promoting water and dampness. The drug compatibility of Crataegi Fructus-Alismatis Rhizoma, Salviae Miltiorrhizae Radix et Rhizoma-Crataegi Fructus appeared more. Three groups of traditional Chinese medicine cluster combinations and one core formula were obtained. Conclusion Traditional Chinese medicine patent compound is mainly used to treat non-alcoholic fatty liver disease, such as soothing liver and strengthening spleen, promoting blood circulation and removing blood stasis, clearing heat and detoxification, removing turbidity and reducing lipid. Medication is peaceful, treating both manifestation and root cause of disease. Its core drug composition can provide reference for clinical medication.

Key words： Non-alcoholic fatty liver disease Traditional Chinese medicine compound National patent Medication rule

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHI Xiaojun TAN Xiang ZHANG Xiaosi ZHANG Xiancui LI Junxiang

Cite this article:

SHI Xiaojun TAN Xiang ZHANG Xiaosi ZHANG Xiancui LI Junxiang. Discussion on medication rule of non-alcoholic fatty liver disease based on national patent of traditional Chinese medicine compound[J]. 中国医药导报, 2022, 19(20): 148-151,156.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I20/148

[1] Sheka AC，Adeyi O，Thompson J，et al. Nonalcoholic steatohepatitis：a review [J]. JAMA，2020，323（12）：1175-1183.
[2] 中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南（2018年更新版）[J].实用肝脏病杂志，2018， 21（2）：177-186.
[3] Younossi Z，Tacke F，Arrese M，et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [J]. Hepatology，2019，69（6）：2672-2682.
[4] Gou SH，Huang HF，Chen XY，et al. Lipid-lowering，hepatoprotective，and atheroprotective effects of the mixture Hong-Qu and gypenosides in hyperlipidemia with NAFLD rats [J]. J Chin Med Assoc，2016，79（3）：111-121.
[5] Cai Y，Liang Q，Chen W，et al. Evaluation of HuoXueHuaYu therapy for nonalcoholic fatty liver disease：a systematic review and meta-analysis of randomized controlled trial [J]. BMC Complement Altern Med，2019，19（1）：178.
[6] 国家药典委员会.中华人民共和国药典[M].一部.北京：中国医药科技出版社，2020.
[7] 钟赣生.中药学[M].北京：中国中医药出版社，2019.
[8] 赵文霞，张丽慧.非酒精性脂肪性肝病应归属“肝癖”论[J].河南中医，2015，35（8）：1820-1822.
[9] 黄鸿娜，符燕青，黄晶晶，等.非酒精性脂肪肝中医药治疗进展[J].辽宁中医杂志，2020，47（11）：201-203.
[10] 张声生，李军祥.非酒精性脂肪性肝病中医诊疗专家共识意见（2017）[J].临床肝胆病杂志，2017，33（12）：2270-2274.
[11] 李军祥，陈誩，王允亮.非酒精性脂肪性肝病中西医结合诊疗共识意见（2017年）[J].中国中西医结合消化杂志，2017，25（11）：805-811.
[12] 万新焕，王瑜亮，周长征，等.丹参化学成分及其药理作用研究进展[J].中草药，2020，51（3）：788-798.
[13] 封若雨，朱新宇，张苗苗.近五年山楂药理作用研究进展[J].中国中医基础医学杂志，2019，25（5）：715-718.
[14] 何峰，张雪莲，温祥臣.山楂酸对高脂饮食诱导的非酒精性脂肪肝模型小鼠炎症反应及氧化应激的影响[J].中国药房，2019，30（7）：901-905.
[15] Guo R，Shang XY，Lv TM，et al. Phenylpropanoid derivatives from the fruit of Crataegus pinnatifida Bunge and their distinctive effects on human hepatoma cells [J]. Phytochemistry，2019，164：252-261.
[16] 周强，张声生.张声生运用调肝理脾法辨治非酒精性脂肪性肝病经验[J].世界中西医结合杂志，2016，11（4）：470-472.
[17] 麦静愔，陈建杰.陈建杰教授分期论治非酒精性脂肪性肝病的经验报道[J].中国中西医结合杂志，2019，39（10）：1263-1265.
[18] 徐朝阳，叶放.周仲瑛教授从痰湿瘀滞论治非酒精性脂肪性肝病经验[J].中国现代医生，2012，50（36）：81-82.
[19] 王彬，章清华，陈烁，等.从浊毒分期论治非酒精性脂肪性肝病[J].中医杂志，2017，58（5）：387-389.
[20] 胡慧明，朱彦陈，于城安，等.山楂、决明子、泽泻提取物对高脂血症大鼠血脂水平、肝功能及HMGCR表达的影响[J].中成药，2021，43（10）：2830-2834.
[21] 黎运呈，王艳，郑迪，等.山楂叶总黄酮对非酒精性脂肪性肝病肝细胞抗氧化作用的研究[J].中西医结合肝病杂志，2019，29（1）：54-56.
[22] 周琴，段丽，吴利春，等.竹节参与丹参和山楂复方改善小鼠非酒精性脂肪肝作用的实验研究[J].中国临床药理学杂志，2018，34（13）：1532-1535.
[23] 戴江东，林传燕，杨冰，等.泽泻治疗非酒精性脂肪性肝病的作用机制研究[J].中国中药杂志，2020，45（17）：4140-4148.
[24] 李红阁，苏和平.辛伐他汀联合丹栀逍遥散治疗非酒精性脂肪肝81例[J].西部中医药，2017，30（6）：98-100.
[25] 胡冬云，王慧云.疏肝健脾法配合西医常规治疗肝郁脾虚型脂肪性肝病40例临床观察[J].中医药导报，2012， 18（4）：52-54.